Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16919350 | 0.76 | ALDH1A1 (0.33) | BACE1ALDH1A1LMNAGAAPAX8 | |
| SCHEMBL6623764 | 0.73 | SLC6A2 (0.39) | ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL5833030 | 0.67 | — | — | |
| SCHEMBL11245064 | 0.66 | LMNA (0.38) | BACE1ALDH1A1LMNAGAAPAX8 | |
| SCHEMBL28452041 | 0.65 | BACE1 (0.32) | BACE1ALDH1A1LMNAGAAPAX8 | |
| SCHEMBL22780547 | 0.64 | BACE1 (0.32) | BACE1ALDH1A1 | |
| SCHEMBL9034778 | 0.64 | ALDH1A1 (0.38) | BACE1ALDH1A1LMNAGAAPAX8 | |
| SCHEMBL28430320 | 0.62 | BACE1 (0.33) | BACE1ALDH1A1LMNAGAAPAX8 | |
| SCHEMBL28844972 | 0.61 | BACE1 (0.32) | BACE1ALDH1A1LMNAGAAPAX8 | |
| SCHEMBL2350335 | 0.61 | LMNA (0.42) | ALDH1A1LMNAGAAPAX8MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010114921-A1 | EPH RECEPTOR LIGANDS AND METHODS OF USE | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100256214-A1 | EPH RECEPTOR LIGANDS AND METHODS OF USE | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256214-A1 | EPH RECEPTOR LIGANDS AND METHODS OF USE | EPHA2, EPHA4, EPHB4 | BACE1 1909/4885ALDH1A1 2859/4885LMNA 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.